Immune checkpoint inhibitors (ICI) have transformed the treatment landscape of advanced non-small cell lung cancer (NSCLC). Biomarkers are essential for guiding precision immunotherapy. Tissue-based programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) are currently widely used biomarkers for selecting patients for immunotherapy. However, tissue specimens are often difficult to reach and couldn't overcome spatial and temporal heterogeneity. Blood biomarkers offer an alternative non-invasive solution that could provide a complete insight on patient's immune status and tumor as well, and show their potential in predicting the outcome as well as in monitoring response to immunotherapy. In this article, we summarize current knowledge on blood biomarkers in NSCLC patients treated with ICI, and we hope to provide more references for development of novel biomarkers. .
【中文题目：非小细胞肺癌免疫检查点抑制剂治疗相关 外周血生物标志物研究进展】 【中文摘要：以免疫检查点抑制剂（immune checkpoint inhibitors, ICI）为代表的免疫治疗改变了非小细胞肺癌（non-small cell lung cancer, NSCLC）的治疗模式，标志物指导下的免疫治疗是精准治疗的关键。基于组织的程序性死亡受体配体1（programmed cell death ligand 1, PD-L1）和肿瘤突变负荷（tumor mutational burden, TMB）是临床上广泛接受的用于指导免疫治疗的生物标志物，然而组织标本不易获取且难以克服肿瘤的时空异质性。外周血标志物作为组织检测的补充，具有取材方便、无创等优势，同时可涵盖肿瘤和宿主免疫状态两方面的信息，在NSCLC免疫治疗疗效预测及治疗反应动态监测方面的价值日益凸显。本文总结NSCLC免疫检查点抑制剂治疗相关外周血生物标志物的研究进展，旨在为开发新型的生物标志物提供参考。 】 【中文关键词：外周血标志物；免疫检查点抑制剂；肺癌；免疫治疗】.
Keywords: Blood biomarkers; Immmune Checkpoint Inhibitors; Immunotherapy; Lung neoplasms.